OCUMENSION THERAPEUTICS

ocumension-therapeutics-logo

Ocumension Therapeutics is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing, and commercializing first- or best-in-class ophthalmic therapies. The companyโ€™s vision is to provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China. Since the inception, Ocumension Therapeutics has focused on building a platform integrating specialized capabilities in each major functionality involved in an ophthalmic drug's development cycle, from research and development, manufacturing to commercialization. Ocumension Therapeutics believes its platform positions it well to achieve leadership in China ophthalmology, with a first-mover advantage over future competitors.

#People #Financial #More

OCUMENSION THERAPEUTICS

Social Links:

Industry:
Biotechnology Pharmaceutical Therapeutics

Founded:
2017-01-01

Status:
Active

Contact:
+86 (021)-61493800

Email Addresses:
[email protected]

Total Funding:
200 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Content Delivery Network Euro JsDelivr GStatic Google Static Content Pound Sterling IIS 10 Japanese Yen


Current Employees Featured

not_available_image

Ye Liu
Ye Liu Executive Director & CEO @ Ocumension Therapeutics
Executive Director & CEO

not_available_image

Changdong LIU
Changdong LIU CMO & CSO @ Ocumension Therapeutics
CMO & CSO
2018-01-01

not_available_image

Zhaopeng HU
Zhaopeng HU Executive Director, Chief Development Officer @ Ocumension Therapeutics
Executive Director, Chief Development Officer

not_available_image

Qinglei Zuo
Qinglei Zuo Chief Commercial Officer @ Ocumension Therapeutics
Chief Commercial Officer
2021-01-01

not_available_image

Donghong Chen
Donghong Chen Chief Medical Officer @ Ocumension Therapeutics
Chief Medical Officer
2019-10-01

Stock Details


Company's stock symbol is HKG:1477

Investors List

general-atlantic_image

General Atlantic

General Atlantic investment in Series B - Ocumension Therapeutics

Investments List

Date Company Article Money raised
2021-04-14 Alimera Sciences Ocumension Therapeutics investment in Post-IPO Equity - Alimera Sciences 20 M USD
2021-01-03 EyePoint Pharmaceuticals Ocumension Therapeutics investment in Post-IPO Equity - EyePoint Pharmaceuticals 15.7 M USD

More informations about "Ocumension Therapeutics" on Search Engine